New York, NY -- July 15, 2019 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues a new research report on biotech and biopharma stocks.

The interim catalysts announced by biotech and biopharma companies can seem unimportant at the time or fail to attract investor interest. Major products announcement like FDA approval or merger generate huge gain for bio firms, but by then the share price is too high. Sometimes the investment key is to buy on the interim catalysts when the price is lower.

An example would be Northwest Biotherapeutics, Inc. (OTCQB: NWBO), a biotechnology company focused on developing DCVax®, personalized immune therapies for solid tumor cancers, and Amarin Corporation plc (NASDAQ: AMRN) the maker of Vascepa. Both companies have announced recent catalysts.

What milestones and catalysts are in play for these 4 bio companies? See our full report READ MORE
Copy and paste to browser may be required https://tradersnewssource.com/biotech-report-2/


June has been a busy month for Anavex Life Sciences Corp. (NASDAQ: AVXL). Their lead drug candidate is ANAVEX 2-73 and there have been recent developments with their clinical trials.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), the company many investors have followed because of their unique technology of creating fabric out of silkworm silk, has new technology that will revolutionize their process in a factory being built at an offshore location. Find out more in our full report below.


Our full comprehensive report on these companies is available with no obligation READ MORE
Copy and paste to browser may be required https://tradersnewssource.com/biotech-report-2/





Disclosure
 
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
 
TNS LLC has not been compensated; directly or indirectly; for producing or publishing this document.
 
PRESS RELEASE PROCEDURES
 
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
 
NO WARRANTY
 
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
 
NOT AN OFFERING
 
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
 
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
 
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source

 

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.